Clincosm LogoSign in Get a demo

Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection

Sponsor
Molecular Insight Pharmaceuticals, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT01572701
Collaborator
(none)
8
Enrollment
1
Location
1
Arm

Study Details

Study Description

Brief Summary

This is a single arm, open label study of up to 24 high risk prostate cancer patients scheduled for prostatectomy and/or pelvic lymph node dissection. Patients receive a single IV dose of 99mTc-MIP-1404 (study drug) followed by SPECT/CT scan 3-6 hours after injection. As standard of care, patients will undergo prostatectomy and/or pelvic lymph node dissection (PLND) within two weeks of study drug dosing. Patients may receive a second injection of study drug within 24 hours of surgery to measure activity counts in tissue samples post-surgery, but prior to pathology processing. 99mTc-MIP-1404 image data will be evaluated for visible uptake and compared with histopathology.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Jun 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: 20 (±3) mCi of study drug

Drug: 99mTc-MIP-1404
20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline

Outcome Measures

Primary Outcome Measures

  1. Tissue distribution of 20 (± 3) mCi 99mTc-MIP-1404 [Post-procedure]

    99mTc-MIP-1404 image data will be evaluated for visible uptake and compared with histopathology.

Secondary Outcome Measures

  1. Safety of 99mTc-MIP-1404: Change in Vital Signs from Pre-Dose to Post-Dose [Vital signs measurements will be measured, an expected average of 30 minutes before and after study drug injection]

    Summary tables will present change from pre-dose to post-dose vital signs measurements.

  2. Intensity of 99mTc-MIP-1404 Uptake with Respect to PSMA expression [Post-procedure]

    99mTc-MIP-1404 image data will be evaluated for visible uptake and compared with histopathology.

  3. Safety of 99mTc-MIP-1404: Summary of Treatment-Emergent Adverse Events (TEAEs) [Adverse events will be assessed for the duration of the study participation, an expected average of 3 weeks]

    TEAEs will be summarized by the Medical Dictionary for Regulatory Activities (MedDRA) body system and preferred term, by intensity, and by causal relationship to study agent.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Male aged 21 years or older.

  2. Ability to provide signed informed consent and willingness to comply with protocol requirements.

  3. Past biopsy indicating the presence of adenocarcinoma of the prostate gland.

  4. Participant is deemed to be high-risk with potential for pelvic lymph node involvement. The criteria for high-risk are:

  • Patient has PSA value >10 and clinical stage T2 or higher, and Gleason score 8, 9 or 10.

  • Patient has PSA value >20 and clinical stage T2 or higher, and Gleason score

  1. Participant is or will be scheduled to undergo standard of care prostatectomy and/or pelvic lymph node dissection.

  2. Have had (within previous 2 months) or will undergo diagnostic CT or MRI imaging prior to surgery.

  3. Have had (within previous 2 months) or will undergo bone scan imaging prior to surgery.

  4. Participants must agree to use an acceptable form of birth control throughout the study period. Participants must use condoms for a period of seven days after each injection, if engaged in sexual activity.

Exclusion Criteria:

  1. Participants for whom participating would significantly delay the scheduled standard of care therapy.

  2. Participants administered a radioisotope within 5 physical half lives prior to study enrollment.

  3. Participants with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Weill Cornell Medical College New York New York United States 10065

Sponsors and Collaborators

  • Molecular Insight Pharmaceuticals, Inc.

Investigators

  • Principal Investigator: Douglas S Scherr, MD, New York Presbyterian Hospital - Weill Medical College of Cornell University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01572701
Other Study ID Numbers:
  • MIP-TcTx-P104
First Posted:
Apr 6, 2012
Last Update Posted:
Nov 25, 2015
Last Verified:
Nov 1, 2015
Additional relevant MeSH terms:
Prostatic Neoplasms

Study Results

No Results Posted as of Nov 25, 2015